Thomas Grunwald

Title: Thomas Grunwald: Innovator in Respiratory Syncytial Virus Research

Introduction

Thomas Grunwald is a notable inventor based in Bochum, Germany. He has made significant contributions to the field of virology, particularly in the development of vaccines against respiratory syncytial virus (RSV). His work has implications for public health, especially in protecting vulnerable populations from viral infections.

Latest Patents

Grunwald holds a patent for the RSV F-protein and its use. The patent describes a nucleic acid molecule that codes for the F-protein of RSV or a fragment thereof. This invention focuses on the expression of codon-optimized variants of the nucleic acid molecule in a human cell environment. It also includes vectors and compositions comprising these nucleic acid molecules, which can be utilized as vaccines and polypeptides coded by the nucleic acid molecules. The method for the production of these components is also outlined in the patent.

Career Highlights

Throughout his career, Thomas Grunwald has worked with several prominent organizations. He has been associated with Pevion Biotech AG, where he contributed to innovative biotechnological solutions. Additionally, he has been involved with Ruhr-Universität Bochum, furthering research and development in his field.

Collaborations

Grunwald has collaborated with notable colleagues, including Klaus Ueberla and Klaus Überla. These partnerships have enhanced his research efforts and contributed to advancements in virology.

Conclusion

Thomas Grunwald's work in the field of respiratory syncytial virus research exemplifies the impact of innovative thinking in biotechnology. His patent for the RSV F-protein represents a significant step forward in vaccine development, showcasing his dedication to improving public health.